The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported. These molecules display enhanced nitric oxide releasing properties due to the presence of an ionisable moiety. The in vivo analgesic/anti-inflammatory activity was maintained in relation to the parent compounds
A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different ...
We report the synthesis and bio-pharmacological evaluation of a class of pyrrole derivatives featuri...
The development of the coxib family has represented a stimulating approach in the treatment of infla...
The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported....
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported....
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
Herein we report the synthesis, biological evaluation, and docking analysis of a class of cyclooxyge...
A new group of hybrid nitric oxide-releasing anti-inflammatory drugs (NONO-coxibs), in which an O2 ‑...
Following our previous research on anti-inflammatory drugs (NSAIDs), we report here the synthesis of...
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
The design of compounds able to combine the selective inhibition of cyclooxygenase-2 (COX-2) with th...
A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different ...
We report the synthesis and bio-pharmacological evaluation of a class of pyrrole derivatives featuri...
The development of the coxib family has represented a stimulating approach in the treatment of infla...
The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported....
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported....
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
Herein we report the synthesis, biological evaluation, and docking analysis of a class of cyclooxyge...
A new group of hybrid nitric oxide-releasing anti-inflammatory drugs (NONO-coxibs), in which an O2 ‑...
Following our previous research on anti-inflammatory drugs (NSAIDs), we report here the synthesis of...
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
The design of compounds able to combine the selective inhibition of cyclooxygenase-2 (COX-2) with th...
A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different ...
We report the synthesis and bio-pharmacological evaluation of a class of pyrrole derivatives featuri...
The development of the coxib family has represented a stimulating approach in the treatment of infla...